Bolt Biotherapeutics, Inc.
BOLT
$3.68
-$0.18-4.71%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 12.79% | 78.64% | 0.07% | -46.88% | -62.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.79% | 78.64% | 0.07% | -46.88% | -62.68% |
| Cost of Revenue | -49.62% | -52.91% | -50.05% | -42.79% | -32.22% |
| Gross Profit | 56.46% | 63.20% | 57.95% | 42.01% | 25.56% |
| SG&A Expenses | -22.62% | -22.36% | -25.26% | -27.03% | -31.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.41% | -45.26% | -44.25% | -39.24% | -32.42% |
| Operating Income | 46.71% | 52.39% | 49.25% | 38.21% | 27.86% |
| Income Before Tax | 43.33% | 53.30% | 47.12% | 34.42% | 23.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 43.33% | 53.30% | 47.12% | 34.42% | 23.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.33% | 53.30% | 47.12% | 34.42% | 23.35% |
| EBIT | 46.71% | 52.39% | 49.25% | 38.21% | 27.86% |
| EBITDA | 46.83% | 52.83% | 49.83% | 38.68% | 28.25% |
| EPS Basic | 37.93% | 50.70% | 46.20% | 34.82% | 23.94% |
| Normalized Basic EPS | 41.53% | 49.44% | 48.69% | 37.80% | 27.04% |
| EPS Diluted | 37.93% | 50.70% | 46.20% | 34.82% | 23.94% |
| Normalized Diluted EPS | 41.53% | 49.44% | 48.69% | 37.80% | 27.04% |
| Average Basic Shares Outstanding | -8.40% | -5.30% | -2.04% | 0.64% | 0.80% |
| Average Diluted Shares Outstanding | -8.40% | -5.30% | -2.04% | 0.64% | 0.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |